Advertisement
Chile's Institute of Public Health (ISP) (http://www.ispch.cl) issued the Registration Certificate for Mellow Hope's H1N1 Influenza A Vaccine (Virion Split). Mellow Hope's H1N1 vaccine is also the first such type of license in Chile. Mellow Hope is also the first China-based company to acquire the H1N1 vaccine approval from a foreign country. The management of HTDS sees this achievement as a "leg up" on the competition which gives Mellow Hope a significant advantage in South American markets for future expansions.
Advertisement
HTDS' CEO Terry Yuan said, "We think this is a great start of our South American expansion which dates back to March of this year. We see this as a tremendous boost to our South American efforts to market our H1N1 vaccine in that region. The optimism of the Chilean negotiations provides us with a great advantage and helps us to promote the export of our H1N1 vaccine to other South American countries. This competitive edge should speed up our registration progress with other South American authorities, securing our place in these markets."
Hard to Treat Diseases (HTDS) operates two medical subsidiaries in Europe and Mainland China. HTDS is a parent company with operations in Eastern Europe Serbia-based pharmaceutical company Slavica Bio Chem Co. and in China Mellow Hope Inc.
The initial order and dollar sums will be shortly released; however, they are significant.
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters, www.minamargroup.com
SOURCE Hard to Treat Diseases
